Ping Duan1,2, Yong Liu1,2, Jiawen Li3,4. 1. Department of Ophthalmology, The Southwest Hospital, Third Military Medical University, Chongqing, 400038, China. 2. Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, No. 30 Gaotanyan Main Street, Shapingba District, Chongqing City, 400038, China. 3. Department of Ophthalmology, The Southwest Hospital, Third Military Medical University, Chongqing, 400038, China. lijiawen861@sina.com. 4. Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, No. 30 Gaotanyan Main Street, Shapingba District, Chongqing City, 400038, China. lijiawen861@sina.com.
Abstract
PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of anti-inflammatory drugs that are used in ophthalmologic surgery. These drugs do not have a steroid structure, but can inhibit surgery-induced miosis, anterior chamber inflammation, and cystoid macular edema (CME). However, the application of NSAIDs remains controversial. Therefore, we performed a meta-analysis to assess the efficacy and safety of NSAIDs for the treatment of anterior chamber inflammation after cataract surgery. METHODS: Relevant articles were identified from the PubMed, Embase, and Cochrane databases up to October 2016. The therapeutic effect of NSAIDs on anterior chamber inflammation was evaluated. The important outcomes of overall anterior chamber inflammation, freedom from ocular pain, and treatment-related/serious ocular adverse events were analyzed by using a random-effects network meta-analysis. The quality of evidence was assessed via the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach. RESULTS: A total of 19 trials assessing 7,234 patients were included in our meta-analysis. Diclofenac was the most likely to improve anterior chamber inflammation after cataract surgery, followed by nepafenac, ketorolac, bromfenac, and flurbiprofen. Nepafenac was most likely to improve postoperative ocular pain relief, followed by bromfenac and ketorolac. Our analysis of treatment-related/serious ocular adverse events revealed that piroxicam was most likely to have the fewest related adverse events, but the robustness of this finding was low. Diclofenac was another near-ideal drug, followed by nepafenac, bromfenac, and ketorolac. CONCLUSIONS: NSAIDs are effective drugs compared to placebos for the relief of anterior chamber inflammation. Furthermore, diclofenac, nepafenac, ketorolac, and bromfenac demonstrated relatively greater significant effects than those of other NSAIDs.
PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of anti-inflammatory drugs that are used in ophthalmologic surgery. These drugs do not have a steroid structure, but can inhibit surgery-induced miosis, anterior chamber inflammation, and cystoid macular edema (CME). However, the application of NSAIDs remains controversial. Therefore, we performed a meta-analysis to assess the efficacy and safety of NSAIDs for the treatment of anterior chamber inflammation after cataract surgery. METHODS: Relevant articles were identified from the PubMed, Embase, and Cochrane databases up to October 2016. The therapeutic effect of NSAIDs on anterior chamber inflammation was evaluated. The important outcomes of overall anterior chamber inflammation, freedom from ocular pain, and treatment-related/serious ocular adverse events were analyzed by using a random-effects network meta-analysis. The quality of evidence was assessed via the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach. RESULTS: A total of 19 trials assessing 7,234 patients were included in our meta-analysis. Diclofenac was the most likely to improve anterior chamber inflammation after cataract surgery, followed by nepafenac, ketorolac, bromfenac, and flurbiprofen. Nepafenac was most likely to improve postoperative ocular pain relief, followed by bromfenac and ketorolac. Our analysis of treatment-related/serious ocular adverse events revealed that piroxicam was most likely to have the fewest related adverse events, but the robustness of this finding was low. Diclofenac was another near-ideal drug, followed by nepafenac, bromfenac, and ketorolac. CONCLUSIONS: NSAIDs are effective drugs compared to placebos for the relief of anterior chamber inflammation. Furthermore, diclofenac, nepafenac, ketorolac, and bromfenac demonstrated relatively greater significant effects than those of other NSAIDs.
Authors: Dennis S Lam; Emmy Y Li; David F Chang; Ming-Zhi Zhang; Hang-Kai Zhan; Chi-Pui Pang Journal: Clin Exp Ophthalmol Date: 2009-07 Impact factor: 4.207
Authors: Stephen J Kim; Scott D Schoenberger; Jennifer E Thorne; Justis P Ehlers; Steven Yeh; Sophie J Bakri Journal: Ophthalmology Date: 2015-06-26 Impact factor: 12.079
Authors: W Andrew Maxwell; Harvey J Reiser; Robert H Stewart; H Dwight Cavanagh; Thomas R Walters; Dana P Sager; Patricia A Meuse Journal: J Ocul Pharmacol Ther Date: 2008-12 Impact factor: 2.671
Authors: Robert H Stewart; Lisa R Grillone; Mitchell L Shiffman; Eric D Donnenfeld; James A Gow Journal: J Ocul Pharmacol Ther Date: 2007-12 Impact factor: 2.671
Authors: Ana María Chinchurreta Capote; Mercedes Lorenzo Soto; Francisco Rivas Ruiz; Enrique Caso Peláez; Alicia García Vazquez; Antonio Ramos Suárez Journal: Int J Ophthalmol Date: 2018-07-18 Impact factor: 1.779
Authors: Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader Journal: Drug Deliv Transl Res Date: 2021-06 Impact factor: 4.617